Moleculin Biotech Inc (MBRX) — Strategic Asset Allocation Index
Moleculin Biotech Inc (MBRX) has a Strategic Asset Allocation Index of 1.5% as of June 2023. Strategic assets (PP&E of $587.00K plus long-term investments of $-) total $587.00K, measured against net assets of $40.27 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Moleculin Biotech Inc Strategic Asset Allocation Index (2016–2021)
This chart shows how Moleculin Biotech Inc's Strategic Asset Allocation Index has evolved across 6 annual periods from 2016 to 2021. As of June 2023, the index stands at 1.5%, representing strategic assets of $587.00K against net assets of $40.27 Million USD. Explore MBRX cash generation efficiency to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Moleculin Biotech Inc (2016–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Moleculin Biotech Inc from 2016 to 2021, covering 6 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Moleculin Biotech Inc market capitalisation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 0.6% | $445.00K | $445.00K | $- | $78.99 Million | ▼ -3.3 pp |
| 2020 | 3.8% | $685.00K | $685.00K | $- | $17.89 Million | ▼ 0.0 pp |
| 2019 | 3.9% | $603.00K | $603.00K | $- | $15.57 Million | ▲ +0.6 pp |
| 2018 | 3.2% | $463.00K | $463.00K | $- | $14.27 Million | ▲ +3.1 pp |
| 2017 | 0.2% | $33.00K | $33.00K | $- | $17.12 Million | ▲ +0.0 pp |
| 2016 | 0.2% | $23.00K | $23.00K | $- | $14.96 Million | — |